AUTHOR=Oostenbrink Lisa V. E. , Jol-van der Zijde Cornelia M. , Kielsen Katrine , Jansen-Hoogendijk Anja M. , Ifversen Marianne , Müller Klaus G. , Lankester Arjan C. , van Halteren Astrid G. S. , Bredius Robbert G. M. , Schilham Marco W. , van Tol Maarten J. D. TITLE=Differential Elimination of Anti-Thymocyte Globulin of Fresenius and Genzyme Impacts T-Cell Reconstitution After Hematopoietic Stem Cell Transplantation JOURNAL=Frontiers in Immunology VOLUME=10 YEAR=2019 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.00315 DOI=10.3389/fimmu.2019.00315 ISSN=1664-3224 ABSTRACT=
Anti-thymocyte globulin (ATG) is a lymphocyte depleting agent applied in hematopoietic stem cell transplantation (HSCT) to prevent rejection and Graft-vs.-Host Disease (GvHD). In this study, we compared two rabbit ATG products, ATG-Genzyme (ATG-GENZ), and ATG-Fresenius (ATG-FRES), with respect to dosing, clearance of the active lymphocyte binding component, post-HSCT immune reconstitution and clinical outcome. Fifty-eigth pediatric acute leukemia patients (